When a 30-person Austrian startup gets showcased by Jensen Huang, CEO of the trillion-dollar tech giant NVIDIA, schedules tend to fill up fast. That’s precisely the case for Innophore, a biotech company tapping NVIDIA’s computational clout with its Catalophore platform to accelerate AI-driven drug safety screening and binding-site analysis. This year, the company was highlighted…
2024: The year AI drug discovery and protein structure prediction took center stage—2025 set to amplify growth
The global AI drug discovery market, valued around $1 to $1.7 billion in 2023, will be worth a multiple of that by the decade’s end. Analysts project the sector could be worth $9 billion or more. 2024 Nobel Prize in Chemistry Recipients: David Baker Demis Hassabis John Jumper Achievement: Computational protein design and structure prediction…
The latest on Isomorphic Labs’ plans to use AI models to revamp drug discovery
“Nearly all diseases stem from a molecular mechanism going wrong,” writes Sergei Yakneen, chief technology officer of Alphabet’s Isomorphic Labs in a recent blog post. “Whether it’s an infectious agent disrupting our cellular machinery or a breakdown in processes like DNA repair, identifying the right protein and finding molecules to interact with it is…
Laying the groundwork to tap AlphaFold 3’s potential in drug discovery
Last week, Google DeepMind launched AlphaFold 3, a significant update to its predecessor, AlphaFold 2. The latter has profoundly influenced structural biology and biomedicine in recent years while also attracting some skepticism. While AlphaFold 2 could accurately predict the structures of vast swathes of proteins, AlphaFold 3 ups the ante. It offers higher accuracy and…
Meet AlphaFold 3, which can accurately model more than 99% of molecular types in the Protein Data Bank
Isomorphic Labs and Google DeepMind have unveiled AlphaFold 3, a powerful AI system that draws on a novel diffusion-based architecture to accurately model the structures of complexes containing proteins, nucleic acids, DNA and RNA strands, small molecules, ions and modified residues. Diffusion models are a type of generative model that has won significant popularity in…
From AI transformers to computer-based reasoning to rethinking drug design: AI pioneers discuss the future
In a packed panel discussion at GTC, moderated by NVIDIA Founder and CEO Jensen Huang, the architects of the groundbreaking transformer model gathered to explore their creation’s potential. The panel featured seven of the eight authors of the seminal “Attention Is All You Need Paper” paper, which introduced transformers — a type of neural network…
Denmark teams up with Novo Nordisk Foundation, NVIDIA to launch visionary AI research center
A collaboration between the Novo Nordisk Foundation, the Export and Investment Fund of Denmark (EIFO), and NVIDIA will establish a national AI Innovation Centre in Denmark focused on accelerating research and innovation in fields including healthcare, life science, and quantum computing. The initiative is led on the Danish side by the Novo Nordisk Foundation, which…
Iambic Therapeutics and NVIDIA partner to slash cancer drug development timelines
Using generative AI in drug discovery, Iambic Therapeutics (formerly Entos) has advanced its IAM1363 drug candidate from program launch to clinical studies in fewer than 24 months — a process that often takes several years. Iambic Therapeutics’ AI drug development milestone relied on an alliance with NVIDIA researchers and engineers and through the use of…
NVIDIA and AWS collaborate to bring BioNeMo AI platform to the cloud
Chipmaker NVIDIA and cloud behemoth AWS have been partnering for years, and now the two companies are announcing that NVIDIA’s drug discovery generative AI platform, BioNeMo, is now available on AWS. Additionally, plans are underway for BioNeMo to be offered on AWS on NVIDIA DGX Cloud. The alliance was announced at the AWS re:Invent event.…
Decoding the enigma of the commander complex: Employing AlphaFold2 to illuminate biological structures
Machine learning algorithms, such as Alphabet’s neural network-based model AlphaFold2, are steadily transforming medical research, shedding light on complex biological structures. A recent case in point involves research using the technology to explore the Commander complex, a 16-protein complex crucial for cellular protein transport processes. This complex is not only vital for normal cellular function,…